IgG1 plasmacytosis in interleukin 6 transgenic mice
Open accessAbstract
Interleukin 6 (IL-6) has been suggested to be involved in the pathogenesis of polyclonal and monoclonal plasma cell abnormalities. To address this possibility, transgenic mice carrying the human IL-6 genomic gene fused with a human immunoglobulin heavy chain enhancer were generated. High concentrations of human IL-6 and polyclonal increase in IgG1 (120- to 400-fold) in sera of all transgenic mice were observed. A massive plasmacytosis in thymus, lymph node, and spleen and an infiltration of plasma cells in lung, liver, and kidney were observed. However, the plasma cells were not transplantable to syngeneic mice and were found not to contain chromosomal aberrations including c-myc gene rearrangements. The evidence indicates that deregulated gene expression of IL-6 can trigger polyclonal plasmacytosis but cannot induce plasmacytoma. It is suggested that additional genetic changes may be required for the generation of plasma cell neoplasia. Other interesting findings in these transgenic mice were the development of mesangio-proliferative glomerulonephritis and an increase in megakaryocytes in bone marrow.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
IL-6 transgenic mice show severe plasmacytosis with hypergammaglobulinemia, while IL-6-deficient mice are defective in immunoglobulin production.
“IL-6 transgenic mice show severe plasmacytosis with hypergammaglobulinemia (147), while IL-6-deficient mice are defective in immunoglobulin production (148, 149).”
From IL-6 in inflammation, autoimmunity and cancer (2021) · cites this paper as [147]
IL-6 transgenic mice develop polyclonal plasmacytosis and monoclonal plasmacytoma in C57BL/6 and BALB/c genetic backgrounds, respectively.
“Accordingly, IL-6 transgenic mice develop polyclonal plasmacytosis and monoclonal plasmacytoma in C57BL/6 and BALB/c genetic backgrounds, respectively (147, 246).”
From IL-6 in inflammation, autoimmunity and cancer (2021) · cites this paper as [147]
Cites
Hirano, T., Taga, T., Yasukawa, K., Nakajima, K., Nakano, N., Takatsuki, F., Shimizu, M., Murashima, A., Tsunasawa, S., & Sakiyama, F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.1.228 · Cited by 351 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
IL-6 in inflammation, autoimmunity and cancer
Hirano, T. (2021) · International Immunology · doi:10.1093/intimm/dxaa078 · Cited by 1,453 · see citing works
“Accordingly, IL-6 transgenic mice develop polyclonal plasmacytosis and monoclonal plasmacytoma in C57BL/6 and BALB/c genetic backgrounds, respectively (147, 246).”
BackgroundSelf-citationThe Pathophysiologic Roles of Interleukin-6 in Human Disease
Papanicolaou, D. A., Wilder, R. L., Manolagas, S. C., & Chrousos, G. P. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-2-199801150-00009 · Cited by 1,146 · see citing works
Targeting Interleukin-6 Signaling in Clinic
Kang, S., Tanaka, T., Narazaki, M., & Kishimoto, T. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.026 · Cited by 870 · see citing works
Self-citationInflammation as a Tumor Promoter in Cancer Induction
Philip, M., Rowley, D. A., & Schreiber, H. (2004) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2004.06.006 · Cited by 640 · see citing works
Pleiotropy and specificity: insights from the interleukin 6 family of cytokines
Murakami, M., Kamimura, D., & Hirano, T. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.027 · Cited by 533 · see citing works
Self-citationTsujinaka, T., Fujita, J., Ebisui, C., Yano, M., Kominami, E., Suzuki, K., Tanaka, K., Katsume, A., Ohsugi, Y., Shiozaki, H., et al. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118398 · Cited by 421 · see citing works
Lymphoproliferative disorder and imbalanced T-helper response in C/EBP beta-deficient mice
Screpanti, I., Romani, L., Musiani, P., Modesti, A., Fattori, E., Lazzaro, D., Sellitto, C., Scarpa, S., Bellavia, D., & Lattanzio, G. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb07185.x · Cited by 407 · see citing works
IL-6: Insights into Novel Biological Activities
Barton, B. E. (1997) · Clinical Immunology and Immunopathology · doi:10.1006/clin.1997.4420 · Cited by 269 · see citing works
The Functional Block of TNF but Not of IL-6 Prevents Bone Loss in Ovariectomized Mice
Kimble, R. B., Bain, S., & Pacifici, R. (1997) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1997.12.6.935 · Cited by 241 · see citing works
Ernst, M., Inglese, M., Waring, P., Campbell, I. K., Bao, S., Clay, F. J., Alexander, W. S., Wicks, I. P., Tarlinton, D. M., Novak, U., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.2.189 · Cited by 227 · see citing works
Tang, W., Geba, G. P., Zheng, T., Ray, P., Homer, R. J., Kuhn, C., Flavell, R. A., & Elias, J. A. (1996) · Journal of Clinical Investigation · doi:10.1172/jci119113 · Cited by 210 · see citing works
Inhibition of IL-6 for the treatment of inflammatory diseases
NISHIMOTO, N. (2004) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2004.03.005 · Cited by 200 · see citing works
Role of Interleukin-6 in Vascular Health and Disease
Villar-Fincheira, P., Sanhueza-Olivares, F., Norambuena-Soto, I., Cancino-Arenas, N., Hernandez-Vargas, F., Troncoso, R., Gabrielli, L., & Chiong, M. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.641734 · Cited by 154 · see citing works
Katsume, A., Saito, H., Yamada, Y., Yorozu, K., Ueda, O., Akamatsu, K.-I., Nishimoto, N., Kishimoto, T., Yoshizaki, K., & Ohsugi, Y. (2002) · Cytokine · doi:10.1006/cyto.2002.2012 · Cited by 134 · see citing works
Self-citationHirano, T., & Kishimoto, T. (1990) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-49295-2_14 · Cited by 57 · see citing works
Self-citationLin, W. W., Yi, Z., Stunz, L. L., Maine, C. J., Sherman, L. A., & Bishop, G. A. (2015) · Science Signaling · doi:10.1126/scisignal.aaa5157 · Cited by 50 · see citing works
- Authors
- Suematsu, S., Matsuda, T., Aozasa, K., Akira, S., Nakano, N., Ohno, S., Miyazaki, J., Yamamura, K., Hirano, T., & Kishimoto, T.
- Affiliations
- The University of Osaka (JP)
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 1989-10
- Volume
- 86
- Issue
- 19
- Pages
- 7547-7551
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC298102
- OpenAlex
- W2060912271
- Cited by
- 586
- References
- 1
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 3 · 2023: 5 · 2022: 6 · 2021: 10 · 2020: 12 · 2019: 19 · 2018: 9 · 2017: 8 · 2016: 10 · 2015: 11 · 2014: 9 · 2013: 7 · 2012: 10
- FWCI
- 23.37
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- interleukin-6, transgenic mice, plasma cell neoplasms, plasmacytoma, c-myc gene rearrangement, megakaryocytes, immunoglobulin heavy chain enhancer, gene expression dysregulation
- MeSH terms
- Animals, Genes, Humans, Immunoglobulin G, Immunoglobulins, Mice, Transgenic, Plasmacytoma, Blotting, Northern, Restriction Mapping, Interleukin-6, Gene Expression, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
